cilengitide has been researched along with Invasiveness, Neoplasm in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Böhmer, FD; Braunsdorf, WE; Hass, P; Helbing, C; Kirches, E; Kliese, N; Mawrin, C; Pachow, D; Pasemann, D; Schneider, T; Warnke, JP; Wilisch-Neumann, A | 1 |
| Date, I; Ichikawa, T; Kurozumi, K; Onishi, M | 2 |
| Cheng, NC; Reid, G; van Zandwijk, N | 1 |
| Adamska, K; Aldape, KD; Brandes, AA; Erridge, SC; Gorlia, T; Grujicic, D; Gupta, T; Hau, P; Hegi, ME; Herrlinger, U; Hicking, C; Hong, YK; Kim, CY; Kortmann, RD; Lhermitte, B; Markivskyy, A; McBain, C; Nabors, LB; Nam, DH; Perry, J; Picard, M; Pietsch, T; Rao, N; Reardon, DA; Schnell, O; Shen, CC; Steinbach, JP; Stupp, R; Taphoorn, MJ; Tarnawski, R; Thurzo, L; Tonn, JC; van den Bent, MJ; Weller, M; Weyerbrock, A; Wick, W; Wiegel, T | 1 |
| D'Atri, S; Graziani, G; Lacal, PM; Levati, L; Ruffini, F; Tentori, L | 1 |
| Date, I; Ichikawa, T; Ishida, J; Kurozumi, K; Shimizu, T | 1 |
| Adams, B; Maurer, GD; Stupp, R; Tabatabai, G; Tritschler, I; Weller, M; Wick, W | 1 |
| Imaizumi, N; Kuonen, F; Monnier, Y; Rüegg, C | 1 |
| Bäuerle, T; Berger, MR; Bretschi, M; Komljenovic, D; Merz, M; Semmler, W | 1 |
| Date, I; Fujii, K; Ichikawa, T; Kurozumi, K; Onishi, M | 1 |
| Chiocca, EA; Date, I; Fujii, K; Ichikawa, T; Inoue, S; Kaur, B; Kurozumi, K; Michiue, H; Onishi, M; Yoshida, K | 1 |
| Sasaki, H; Yoshida, K | 1 |
5 review(s) available for cilengitide and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Cell Adhesion; Combined Modality Therapy; Glioblastoma; Humans; Integrin alphaVbeta3; Neoplasm Invasiveness; Neoplasm Proteins; Neovascularization, Pathologic; Snake Venoms; Vascular Endothelial Growth Factor A | 2013 |
Adhesion molecules and the extracellular matrix as drug targets for glioma.
Topics: Angiogenesis Inhibitors; Antibodies; Brain Neoplasms; Cell Adhesion Molecules; Disease Progression; Extracellular Matrix; Glioma; Humans; Molecular Targeted Therapy; Neoplasm Invasiveness; Neovascularization, Pathologic; Snake Venoms; Thalidomide; White Matter | 2016 |
Angiogenesis and invasion in glioma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Disease Models, Animal; Endothelial Cells; Extracellular Matrix; Glioma; Humans; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neovascularization, Pathologic; Rats; Snake Venoms; Tenascin; Thalidomide | 2011 |
Cilengitide treatment for malignant glioma: current status and future direction.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Integrins; Neoplasm Invasiveness; Snake Venoms | 2012 |
[Inhibition of cellular adhesion and invasion in gliomas].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cathepsin B; Cell Adhesion; Clinical Trials as Topic; Drug Design; Extracellular Matrix; Glioma; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydroxamic Acids; Integrins; Laminin; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Multigene Family; Neoplasm Invasiveness; Signal Transduction; Snake Venoms; Urokinase-Type Plasminogen Activator | 2005 |
1 trial(s) available for cilengitide and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Detection of Cancer; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Promoter Regions, Genetic; Proportional Hazards Models; Reference Values; Snake Venoms; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
7 other study(ies) available for cilengitide and Invasiveness, Neoplasm
| Article | Year |
|---|---|
The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Disease Models, Animal; Humans; Immunohistochemistry; Integrins; Meningeal Neoplasms; Meningioma; Mice; Neoplasm Invasiveness; Neurofibromin 2; Receptors, Vitronectin; Snake Venoms; Tumor Burden | 2013 |
Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.
Topics: Cell Adhesion; Cell Line, Tumor; Humans; Integrin alphaVbeta3; Mesothelioma; Neoplasm Invasiveness; Pleural Neoplasms; Receptors, Vitronectin; Snake Venoms | 2014 |
Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin.
Topics: Cell Line, Tumor; Focal Adhesion Protein-Tyrosine Kinases; Humans; Melanoma; Neoplasm Invasiveness; Neuropilin-1; Receptors, Vitronectin; Snake Venoms; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; DNA Methylation; Drug Therapy, Combination; Gene Silencing; Glioma; Humans; Immunoblotting; In Vitro Techniques; Integrin alphaVbeta3; Mice; Neoplasm Invasiveness; NIH 3T3 Cells; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, Vitronectin; Snake Venoms; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2009 |
Radiation-induced modifications of the tumor microenvironment promote metastasis.
Topics: Angiogenesis Inhibitors; Cell Hypoxia; Cell Movement; Cell Proliferation; Cysteine-Rich Protein 61; Disease Progression; Endothelial Cells; Humans; Microvessels; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Receptors, Vitronectin; Snake Venoms; Tumor Microenvironment | 2011 |
Cilengitide inhibits metastatic bone colonization in a nude rat model.
Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Female; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Osteoclasts; Rats; Rats, Nude; Snake Venoms; Xenograft Model Antitumor Assays | 2011 |
Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Coculture Techniques; Disease Models, Animal; Dogs; Glioma; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Rats; Rats, Nude; Snake Venoms; Xenograft Model Antitumor Assays | 2013 |